Inscripta Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 77

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.85M

  • Investors
  • 23

Inscripta General Information

Description

Developer of a gene-editing technology intended to offer scalable digital genome engineering with push-button simplicity. The company's technology generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined and trackable mutations, enabling researchers to design, engineer, evaluate and track results.

Contact Information

Formerly Known As
Muse Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Devices and Supplies
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • 5720 Stoneridge Drive
  • Suite 300
  • Pleasanton, CA 94588
  • United States
+1 (925) 000-0000

Inscripta Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inscripta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 31-May-2023 $1.85M 00000 Completed Generating Revenue
7. Later Stage VC (Series E) 05-Apr-2021 00000 00000 00.00 Completed Generating Revenue
6. Later Stage VC (Series D) 30-Nov-2020 0000 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series D) 11-Nov-2019 00000 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series C1) 29-Mar-2019 0000 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 28-Feb-2019 000.00 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 16-Feb-2017 $23M $29M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 10-May-2016 $6.04M $6.04M 0000 Completed Startup
To view Inscripta’s complete valuation and funding history, request access »

Inscripta Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 19,784,629 $0.000010 6% $1.17 $1.17 1x $1.17 13.44%
Series A 5,157,970 $0.000010 6% $1.17 $1.17 1x $1.17 3.5%
To view Inscripta’s complete cap table history, request access »

Inscripta Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene-editing technology intended to offer scalable digital genome engineering with push-button simplicity
Other Devices and Supplies
Pleasanton, CA
77 As of 2024
00000
0000000000 0 00000

000000

llamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in
0000000000 000000000
San Diego, CA
0000 As of 0000
00.000
0000 00.000

0000 0

reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. E
0000 000000000
Toronto, Canada
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inscripta Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Illumina Formerly VC-backed San Diego, CA 0000 00.000 0000 00.000
Deep Genomics Venture Capital-Backed Toronto, Canada 000 00000 00000000000 00000
Synthego Venture Capital-Backed Redwood City, CA 000 00000 00000000000 00000
EdiGene Venture Capital-Backed Beijing, China 000 00000 00000000000 00000
Human Longevity Venture Capital-Backed San Diego, CA 00 00.000 0000000000 0 00.000
You’re viewing 5 of 5 competitors. Get the full list »

Inscripta Patents

Inscripta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240076697-A1 Methods for increased nucleic acid-guided cell editing Pending 01-Sep-2022 0000000000
US-20240101614-A1 Chaperones for heterologous expression systems Pending 25-Aug-2022 0000000000
US-20240052370-A1 Modulating cellular repair mechanisms for genomic editing Pending 27-Jul-2022 000000000
US-20230340448-A1 Engineered enzymes and bioproduction of bakuchiol Pending 04-Mar-2022 00000000
US-20230136423-A1 Nuclease-mediated plasmid integration Pending 29-Oct-2021 C12N9/22
To view Inscripta’s complete patent history, request access »

Inscripta Executive Team (15)

Name Title Board Seat Contact Info
Sri Kosaraju Chief Executive Officer, President & Board Member
Ron Mcgrath Chief Financial Officer
Atulya Agarwal JD Chief Legal Officer
Michael Seater Controller
Andrew Garst Ph.D Co-Founder & Scientific Advisor Board
You’re viewing 5 of 15 executive team members. Get the full list »

Inscripta Board Members (7)

Name Representing Role Since
Bryan Roberts Ph.D Venrock Board Member 000 0000
Eric Moessinger ND Capital Board Observer 000 0000
John Stuelpnagel Self Chairman 000 0000
Kristala Prather Self Board Member 000 0000
Roger Wyse Ph.D Spruce Capital Partners Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Inscripta Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inscripta Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Counterpoint Global Asset Manager Minority 000 0000 000000 0
D1 Capital Partners Hedge Fund Minority 000 0000 000000 0
Durable Capital Partners Hedge Fund Minority 000 0000 000000 0
Fidelity Management & Research Asset Manager Minority 000 0000 000000 0
GoldenArc Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 23 investors. Get the full list »

Inscripta Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sestina Bio 18-Jan-2023 0000000000 Other Healthcare Technology Systems
Infinome Biosciences 12-Dec-2022 0000000000 Biotechnology 000 00000
Solana Biosciences 05-Sep-2018 Merger/Acquisition Biotechnology 00000 000
To view Inscripta’s complete acquisitions history, request access »

Inscripta Subsidiaries (1)

Company Name Industry Location Founded
Sestina Bio Other Healthcare Technology Systems Pleasanton, CA 0000
To view Inscripta’s complete subsidiaries history, request access »

Inscripta FAQs

  • When was Inscripta founded?

    Inscripta was founded in 2015.

  • Who is the founder of Inscripta?

    Tanya Lipscomb Ph.D, Andrew Garst Ph.D, and Ryan Gill Ph.D are the founders of Inscripta.

  • Who is the CEO of Inscripta?

    Sri Kosaraju is the CEO of Inscripta.

  • Where is Inscripta headquartered?

    Inscripta is headquartered in Pleasanton, CA.

  • What is the size of Inscripta?

    Inscripta has 77 total employees.

  • What industry is Inscripta in?

    Inscripta’s primary industry is Other Devices and Supplies.

  • Is Inscripta a private or public company?

    Inscripta is a Private company.

  • What is Inscripta’s current revenue?

    The current revenue for Inscripta is 00000.

  • How much funding has Inscripta raised over time?

    Inscripta has raised $461M.

  • Who are Inscripta’s investors?

    Counterpoint Global, D1 Capital Partners, Durable Capital Partners, Fidelity Management & Research, and GoldenArc are 5 of 23 investors who have invested in Inscripta.

  • Who are Inscripta’s competitors?

    Illumina, Deep Genomics, Synthego, EdiGene, and Human Longevity are competitors of Inscripta.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »